MANGOCEUTICALS, INC. Files 8-K with Key Corporate Actions
Ticker: MGRX · Form: 8-K · Filed: Jul 2, 2024 · CIK: 1938046
| Field | Detail |
|---|---|
| Company | Mangoceuticals, INC. (MGRX) |
| Form Type | 8-K |
| Filed Date | Jul 2, 2024 |
| Risk Level | medium |
| Pages | 14 |
| Reading Time | 16 min |
| Key Dollar Amounts | $0.0001, $1,650,000, $1,500,000, $500,000, $250,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, corporate-governance
TL;DR
MANGOCEUTICALS, INC. filed an 8-K on 4/26 detailing material agreements, equity sales, and governance changes.
AI Summary
On April 26, 2024, MANGOCEUTICALS, INC. filed an 8-K report detailing several material events. These include entering into a material definitive agreement, unregistered sales of equity securities, and material modifications to the rights of security holders. The company also submitted matters to a vote of security holders and made amendments to its articles of incorporation or bylaws.
Why It Matters
This filing indicates significant corporate activity and potential changes affecting MANGOCEUTICALS, INC.'s structure and security holders.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce complexities and potential risks for investors.
Key Players & Entities
- MANGOCEUTICALS, INC. (company) — Registrant
- April 26, 2024 (date) — Date of Earliest Event Reported
- Texas (location) — State of Incorporation
- 001-41615 (identifier) — SEC File Number
- 87-3841292 (identifier) — IRS Employer Identification No.
FAQ
What was the nature of the material definitive agreement entered into by MANGOCEUTICALS, INC. on or around April 26, 2024?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.
What type of equity securities were sold in the unregistered sales reported by MANGOCEUTICALS, INC.?
The filing mentions unregistered sales of equity securities, but the specific type and amount of securities are not detailed in the provided text.
What specific modifications were made to the rights of MANGOCEUTICALS, INC. security holders?
The filing notes material modifications to the rights of security holders, but the exact nature of these modifications is not specified in the provided text.
What matters were submitted to a vote of MANGOCEUTICALS, INC. security holders?
The filing states that matters were submitted to a vote of security holders, but the specific proposals or resolutions are not detailed in the provided text.
Were there any amendments to MANGOCEUTICALS, INC.'s articles of incorporation or bylaws?
Yes, the filing indicates amendments to the articles of incorporation or bylaws of MANGOCEUTICALS, INC.
Filing Stats: 4,123 words · 16 min read · ~14 pages · Grade level 14.5 · Accepted 2024-07-02 16:40:31
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 Par Value Per Share MGRX The Nasdaq
- $1,650,000 — B Preferred Stock ") of the Company for $1,650,000, and warrants (the " Initial Warrants "
- $1,500,000 — "), for an aggregate purchase price of $1,500,000, of which $500,000 in shares of Series
- $500,000 — purchase price of $1,500,000, of which $500,000 in shares of Series B Preferred Stock a
- $250,000 — 0, 2024 (the " Second Closing Date ") $250,000 (" Second Closing Amount ") Third Clo
- $750,000 — 1,500,000 On or before June 30, 2024 $750,000 (" Third Closing Amount ") Fourth Clo
- $1,000,000.00 — in the Registration Rights Agreement) $1,000,000.00 (the " Fourth Closing Amount ") Total
- $0.50 — of Common Stock at an exercise price of $0.50 per share (the "$0.50 Warrants "); and
- $1.00 — of Common Stock at an exercise price of $1.00 per share (the " $1.00 Warrants ", and
- $1,100 — ck each have an initial stated value of $1,100 per share (the " Stated Value "), and a
- $1,000,000 — sly had to purchase up to an additional $1,000,000 of Series B Preferred Stock; to amend a
- $0.035 — o increase the floor price thereof from $0.035 per share to $0.15 per share, as discus
- $0.15 — price thereof from $0.035 per share to $0.15 per share, as discussed in greater deta
- $150,000 — the Second Closing, the Purchaser paid $150,000 to the Company and in consideration the
- $100,000 — the Second Closing, the Purchaser paid $100,000 to the Company and in consideration the
Filing Documents
- form8-k.htm (8-K) — 92KB
- ex3-2.htm (EX-3.2) — 17KB
- ex4-1.htm (EX-4.1) — 113KB
- ex4-2.htm (EX-4.2) — 113KB
- ex10-2.htm (EX-10.2) — 49KB
- ex3-2_001.jpg (GRAPHIC) — 247KB
- ex3-2_002.jpg (GRAPHIC) — 111KB
- 0001493152-24-026029.txt ( ) — 1124KB
- mgrx-20240426.xsd (EX-101.SCH) — 3KB
- mgrx-20240426_lab.xml (EX-101.LAB) — 33KB
- mgrx-20240426_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MANGOCEUTICALS, INC. Date: July 2, 2024 By: /s/ Jacob D. Cohen Jacob D. Cohen Chief Executive Officer